Alnylam's $700M investment from Genzyme brings massive stock gains

A deal that an executive at Alnylam Pharmaceuticals called “transformational” not only for the company, but the cutting-edge technology known as RNA interference, boosted the company’s stock price more than 50 percent this morning to a new all-time high...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.